The potential for liquid biopsy in early detection in oncology

Researchers and clinicians work with challenges around evolving treatment strategies to keep up with tumor evolution.

Anticipating and out-maneuvering cancer with actionable diagnostic information to impact clinical decision-making during a patient’s treatment journey is a central theme.

At the seminar, you will see user cases involving clinicians treating patients using real-time oncology enabled by de-centralized testing, including an LDT assay, which is currently being used to simultaneously detect ESR1 and PIK3CA mutations in patients with metastatic breast cancer. 


The seminar will cover:

  • The potential for liquid biopsy in early detection through resistance and recurrence applications;  
  • Using ctDNA molecular endpoint assays to manage and treat disease in real-time;  
  • Allowing for more treatment options for patients, along with expanding the utility of drug therapies at earlier stages of disease. 


The last day for sign-up is October 20, 2023. 

Seats are limited, sign up to the right. Participation is free of charge. 
If you are prevented from participating, please let us know as soon as possible.

   Click and see the invite

Oct. 26, 09:00 - Oct. 26, 10:00
Auditorium B in the Telium Building
Inge Lehmanns Vej 14, stuen
2100 København Ø, Denmark
Register here